الإحصائيات الأساسية
| LEI | 549300I5QGRS3BLHZH41 |
| CIK | 1357874 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Precision BioSciences, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 7, 2025 |
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2 - PBGENE-HBV demonstrated substantial antiviral activity in all Cohort 1 patients, with best responses achieving a 47-69% |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2025 |
2019 Incentive Award Plan, and forms of award agreements thereunder PRECISION BIOSCIENCES, INC. 2019 INCENTIVE AWARD PLAN (As Amended and Restated Effective June 4, 2024) ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are de |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 6, 2025 |
Exhibit 99.1 Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B - Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of complete cure - Coh |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| May 15, 2025 |
Exhibit 99.1 Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision’s in vivo gene editing approach - Announced initial data from first cohort in the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV; initial safety data presented at EASL; ongoi |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2025 |
Exhibit 99.1 Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of th |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| April 4, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the |
|
| March 26, 2025 |
Up to $14,868,926 Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-272540 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement dated June 15, 2023) Up to $14,868,926 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus, dated June 15, 2023, filed with the Securities and Exchange Commission as part of our registration sta |
|
| March 26, 2025 |
Exhibit 99.1 Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update • Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - • Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for |
|
| March 26, 2025 |
Precision BioSciences, Inc. Insider Trading Compliance Policy Exhibit 19.1 Precision BioSciences, Inc. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company to preve |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38841 Precision BioSc |
|
| March 26, 2025 |
Description of Registrant’s Securities. Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2024, Precision BioSciences, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the “Company” refer to Precision Bi |
|
| March 26, 2025 |
Subsidiaries of Precision BioSciences, Inc. Exhibit 21.1 Subsidiaries Precision BioSciences, Inc. has no subsidiaries. |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 14, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p25-0291exhibit991.htm JOINT ACQUISITION STATEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity |
|
| February 12, 2025 |
EVIDENCE OF SIGNATORY AUTHORITY EX-99.1 2 tm255748d1ex99-1.htm EXHIBIT 1 EXHIBIT 1 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis Pharma AG Identification number Legal status Entry Cancelled Carried CH-270.3.004.604-7 from: CH-270.3.004.604-7/b 1 CHE-106.052.527 Limited or Corporation 25.10.1989 on: All data In Ca Business name Ref Legal seat 1 Novartis Pharma AG 1 Basel 1 (Novartis Pharma SA) (Nova |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 8, 2025 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 14, 2024 |
SC 13G/A 1 pbio1015240sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Precision BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.000005 per share (Title of Class of Securities) 74019P207 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement |
|
| November 14, 2024 |
DTIL / Precision BioSciences, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d911990dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Precision Biosciences, Inc. (Name of Issuer) Common Stock, par value $$0.000005 per share (Title of Class of Securities) 74019P207 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta |
|
| November 14, 2024 |
SC 13G 1 p24-3246sc13g.htm PRECISION BIOSCIENCES INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Precision BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.000005 per share (Title of Class of Securities) 74019P207 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this stateme |
|
| November 14, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.000005 par value per share, of Precision BioSciences, Inc. and further agree to the fil |
|
| November 4, 2024 |
Exhibit 99.1 Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval - Opened PBGENE-HBV phase 1 clinical program in Moldova; patient screening underway with |
|
| November 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 4, 2024 |
Consulting Agreement between Precision BioSciences, Inc. and Dr. Alan List, dated September 13, 2024 Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential CONSULTING AGREEMENT This CONSULTING AGREEMENT (“Agreement”) is made by and between Precision BioSciences, Inc., a Delaware corporation having a place of business at 302 East Pettigrew Street, Dibrell Building, Su |
|
| November 4, 2024 |
EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.5 EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Eighth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of June 21, 2024, by and between Banc of California, a California state-chartered bank (formerly known as Pacific Western Bank) (“Bank”) and PRECISION BIOSCIENCES, INC. (“Precision” or “Borrower”). RECITALS Borrower and Bank are parties to that cer |
|
| November 4, 2024 |
PRECISION BIOSCIENCES, INC. AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.7 PRECISION BIOSCIENCES, INC. AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of July 31, 2024, by and between Banc of California, a California state-chartered bank (“Bank”) and PRECISION BIOSCIENCES, INC. (“Borrower”). RECITALS A. Borrower and Bank have entered into that certain Loan and Securit |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| October 24, 2024 |
Exhibit 99.1 Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Clinical Trial Application accepted in Moldova with additional regulatory applications pending approval - PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move into global clinical trials |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 12, 2024 |
Exhibit 99.1 Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution - Murray Abramson, MD, MPH appointed as Senior Vice President, Head of Clinical Development - John Fry appointed as Strategic Clinical Advisor, Hepatitis – - Alan List, MD, Chief Medical Officer to Retire and Assume Role as Clinical Consultant as part of Precision’s Scientific A |
|
| September 3, 2024 |
Exhibit 99.1 Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal - Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares- -The addition of this cash further reinforces Precision’s expected cash runway into the second half of 2026- DURHAM, N.C.—September 3, 2024- Precision BioScienc |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| August 1, 2024 |
Exhibit 10.7 PRECISION BIOSCIENCES, INC. AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of July 31, 2024, by and between Banc of California, a California state-chartered bank (“Bank”) and PRECISION BIOSCIENCES, INC. (“Borrower”). RECITALS A. Borrower and Bank have entered into that certain Loan and Securit |
|
| August 1, 2024 |
Exhibit 99.1 Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Su |
|
| August 1, 2024 |
Exhibit 10.5 EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Eighth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of June 21, 2024, by and between Banc of California, a California state-chartered bank (formerly known as Pacific Western Bank) (“Bank”) and PRECISION BIOSCIENCES, INC. (“Precision” or “Borrower”). RECITALS Borrower and Bank are parties to that cer |
|
| July 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Precision BioSciences, Inc. |
|
| July 1, 2024 |
As filed with the Securities and Exchange Commission on July 1, 2024 As filed with the Securities and Exchange Commission on July 1, 2024 Registration No. |
|
| July 1, 2024 |
2019 Incentive Award Plan, as Amended and Restated, and forms of award agreements thereunder Exhibit 99.1 PRECISION BIOSCIENCES, INC. 2019 INCENTIVE AWARD PLAN (As Amended and Restated Effective June 4, 2024) ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in th |
|
| July 1, 2024 |
Amendment, effective as of June 4, 2024, to the 2021 Employment Inducement Incentive Award Plan. Exhibit 99.4 AMENDMENT TO THE PRECISION BIOSCIENCES, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS AMENDMENT TO THE PRECISION BIOSCIENCES, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this “Amendment”), is effective as of June 4, 2024, the date the board of directors (the “Board”) of Precision BioSciences, Inc., a Delaware corporation (the “Company”), approved the amendment to |
|
| June 10, 2024 |
Exhibit 10.1 PRECISION BIOSCIENCES, INC. 2019 INCENTIVE AWARD PLAN (As Amended and Restated Effective June 4, 2024) ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in th |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| May 13, 2024 |
Exhibit 99.1 Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 - First ARCUS in vivo gene editing program now open for enrollment in the United Kingdom through partnered OTC deficiency prog |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2024 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commission |
|
| April 25, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| April 16, 2024 |
Exhibit 99.1 Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new pa |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 27, 2024 |
Subsidiaries of Precision BioSciences, Inc. Exhibit 21.1 Subsidiaries Precision BioSciences, Inc. has no subsidiaries. |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38841 Precision BioSc |
|
| March 27, 2024 |
Description of Registrant’s Securities. Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2023, Precision BioSciences, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). References herein to “we,” “us,” “our” and the “Company” refer to Precision Bi |
|
| March 27, 2024 |
Exhibit 10.2 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and among TG THERAPEUTICS, INC., TG CELL THERAPY, INC. and PRECISION BIOSCIENCES, INC. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into as of January 7, 2024 (the “Effec |
|
| March 27, 2024 |
Exhibit 99.1 Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update - Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 - Completed licensing agreements to monetize divested CAR T assets with Imugene, TG Therapeutics and Caribou Biosciences including nearly $50 |
|
| March 27, 2024 |
Exhibit 97 PRECISION BIOSCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Precision BioSciences, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject |
|
| March 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 27, 2024 |
Exhibit 10.12 LEASE AGREEMENT BY AND BETWEEN VENABLE TENANT, LLC, as Landlord AND PRECISION BIOSCIENCES, INC., as Tenant TABLE OF CONTENTS Section 1 Defined Terms 3 Section 2 Recitals 7 Section 3 Premises 8 Section 4 Term 8 Section 5 Rent 9 Section 6 Operating Expenses 9 Section 7 Utilities and Services 10 Section 8 Direct Tenant Expenses 11 Section 9 Security Deposit 12 Section 10 Maintenance and |
|
| March 18, 2024 |
DTIL / Precision BioSciences, Inc. / Aquilo Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Precision Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.000005 per share (Title of Class of Securities) 74019P108 (CUSIP Number) March 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| March 14, 2024 |
DTIL / Precision BioSciences, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d780054dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Precision Biosciences, Inc. (Name of Issuer) Common Stock, par value $$0.000005 per share (Title of Class of Securities) 74019P108 (CUSIP Number) March 5, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| March 14, 2024 |
EX-99.1 2 d780054dex991.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: March 14, 20 |
|
| March 4, 2024 |
2,500,000 Shares of Common Stock Warrants to Purchase 2,500,000 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-272540 PROSPECTUS SUPPLEMENT (To Prospectus dated June 15, 2023) 2,500,000 Shares of Common Stock Warrants to Purchase 2,500,000 Shares of Common Stock We are offering 2,500,000 shares of our common stock and accompanying warrants to purchase 2,500,000 shares of our common stock. Each share of our common stock is b |
|
| March 1, 2024 |
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants Free Writing Prospectus pursuant to Rule 433 dated March 1, 2024 Registration Statement No. |
|
| March 1, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Precision BioSciences, Inc. Warrant number: CUSIP No.: 74019P 116 Warrant Shares: Issue Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h |
|
| March 1, 2024 |
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants Exhibit 99.1 Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants DURHAM, N.C.—March 1, 2024 – Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today anno |
|
| March 1, 2024 |
Underwriting Agreement, dated March 1, 2024, between the Company and Guggenheim Securities, LLC Exhibit 1.1 Precision BioSciences, Inc. 2,500,000 Shares of Common Stock, par value $0.000005 per share and Warrants to Purchase 2,500,000 Shares of Common Stock Underwriting Agreement March 1, 2024 Guggenheim Securities LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: Precision BioSciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell t |
|
| March 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2024 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissi |
|
| February 29, 2024 |
Subject to Completion, dated February 29, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 14, 2024 |
DTIL / Precision BioSciences, Inc. / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-dtil123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Precision BioSciences Inc. (Name of Issuer) Common Stock, par value $0.000005 per share (Title of Class of Securities) 74019P108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statemen |
|
| February 13, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PRECISION BIOSCIENCES, INC. Precision BioSciences, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That the Board of Directors of the Corporation duly adopted resolutions recom |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 9, 2024 |
DTIL / Precision BioSciences, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Precision BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74019P108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 5, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.000005 par value per share, of Precision BioSciences, Inc. and further agree to the fil |
|
| February 5, 2024 |
DTIL / Precision BioSciences, Inc. / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 23, 2024 |
Exhibit 10.1 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Michael Amoroso (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “ |
|
| January 23, 2024 |
EXHIBIT 10.3 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Dario Scimeca (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Pa |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 23, 2024 |
EXHIBIT 10.2 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and John Alexander Kelly (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as |
|
| January 23, 2024 |
EXHIBIT 10.4 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 22nd day of January, 2024 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and James Jefferson Smith (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 11, 2024 |
Exhibit 99.1 Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases - Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments - Upfront Cash and Near-Term Payments Expected to Extend Precision’s Cash Runway into the First Half of 2026 a |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 22, 2023 |
Amended and Restated Bylaws of Precision BioSciences, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PRECISION BIOSCIENCES, INC. (a Delaware corporation) as of December 19, 2023 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Def |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ De |
|
| November 7, 2023 |
Exhibit 99.1 Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update - Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 - Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline - Expanded portfolio with PBGENE-PMM as a potentially curative treatment for m.3243 associated primary mitochondr |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 7, 2023 |
Exhibit 10.2 TENTH AMENDMENT TO LEASE AGREEMENT THIS TENTH AMENDMENT TO LEASE AGREEMENT (this “Tenth Amendment”) is made as of the 16th day of October, 2023 (the “Effective Date”) by and between VENABLE HISTORIC, LLC, a Delaware limited liability company (“Landlord”), and PRECISION BIOSCIENCES, INC., a Delaware corporation (“Tenant”), with respect to the following recitals: A. Pursuant to that cer |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of I |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 12, 2023 |
Exhibit 99.1 Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments - Company highlights new preclinical data for wholly-owned and partnered programs following prioritization of in vivo gene editing portfolio - Expands portfolio with PBGENE-PMM as a potentially curative treatment for primary mitochondrial myopa |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 21, 2023 |
Exhibit 10.1 Execution Version Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and between IMUGENE (USA) INC. and PRECISION BIOSCIENCES, INC. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into as of August 15, 2023 (the “Effective D |
|
| August 21, 2023 |
EXHIBIT 2.1 Execution Version Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. ASSET PURCHASE AGREEMENT BY AND AMONG PRECISION BIOSCIENCES, INC., IMUGENE (USA) INC. and IMUGENE LIMITED August 15, 2023 TABLE OF CONTENTS ARTICLE I PURCHASE AND SALE 1 1.1 Purchase and Sale of |
|
| August 21, 2023 |
Precision BioSciences, Inc. Unaudited Pro Forma Condensed Consolidated Financial Statements Exhibit 99.1 Precision BioSciences, Inc. Unaudited Pro Forma Condensed Consolidated Financial Statements On August 15, 2023, Precision BioSciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Imugene Limited, an Australian corporation (“Imugene Limited”), and its wholly owned subsidiary Imugene (USA) Inc. (“Imugene US”), a Nevada corporation (colle |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of In |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 16, 2023 |
Exhibit 99.1 Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer - Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales - Imugene to Assume Control of Precision’s Cell Therapy Infrastructure in Pursuit of Biologics License Application for Azer-Cel in LBCL Patien |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| August 4, 2023 |
Exhibit 99.1 Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update - FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing - Presented Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B - Company plans to host In |
|
| July 6, 2023 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. EXECUTION VERSION amended and restated DEVELOPMENT AND LICENSE AGREEMENT between PREVAIL THERAPEUTICS INC. and PRECISION BIOSCIENCES, INC. Exhibit 10.1 AMENDED AND RESTATED Development AND LICENSE AGREEMENT This |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 13, 2023 |
PRECISION BIOSCIENCES, INC. 302 East Pettigrew St., Suite A-100 Durham, North California 27701 PRECISION BIOSCIENCES, INC. 302 East Pettigrew St., Suite A-100 Durham, North California 27701 June 13, 2023 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: PRECISION BIOSCIENCES, INC. Registration Statement on Form S-3 (Registration No. 333-272540) To the addressee set f |
|
| June 9, 2023 |
Exhibit 4.3 PRECISION BIOSCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 Article II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishme |
|
| June 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Precision BioSciences, Inc. |
|
| June 9, 2023 |
As filed with the Securities and Exchange Commission on June 9, 2023 As filed with the Securities and Exchange Commission on June 9, 2023 Registration No. |
|
| May 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 31, 2023 |
Exhibit 99.1 Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T Related Adverse Events Were Observed Azer-Cel Achieved 83% Overall Response Rate (ORR), 61% Comple |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 9, 2023 |
Exhibit 99.1 Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update - Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT Conference - In Vivo Gene Editing R&D Day Planned for Mid-2023 - Cash Balance Provides Expected Runway thr |
|
| May 9, 2023 |
Non‑Employee Director Compensation Plan (as amended). Exhibit 10.1 Precision BioSciences, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Precision BioSciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program, as amended from time to time (this “Program”). The cash compensation described in this Program shall |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 18, 2023 |
Exhibit 99.1 Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting - Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular Dystrophy DURHAM, N.C.—April 18, 2023- Precision BioSciences, |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 23, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38841 Precision BioSc |
|
| March 9, 2023 |
Subsidiaries of Precision BioSciences, Inc. Exhibit 21.1 Subsidiaries Precision BioSciences, Inc. has no subsidiaries. |
|
| March 9, 2023 |
Exhibit 10.24 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 15th day of March, 2019 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Dario Scimeca (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Par |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 9, 2023 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PRECISION BIOSCIENCES, INC. ELO LIFE SYSTEMS, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of May 15, 2019, by and between PACIFIC WESTERN BANK, a California |
|
| March 9, 2023 |
Exhibit 10.22 AMENDED AND RESTATED Executive EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is made and entered into as of May 27, 2021 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Alex Kelly (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and c |
|
| March 9, 2023 |
Exhibit 10.23 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 26th day of April, 2021 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Dr. Alan List (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Par |
|
| March 9, 2023 |
Exhibit 99.1 Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update - Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day Planned for Mid-2023 - Progressed Azer-cel and PBCAR19B Allogenic CAR T Clinical Studies; Program Updates Planned for Azer-cel and PBCAR19B - Advanced Wholly Owned, Pr |
|
| February 27, 2023 |
DTIL / Precision Biosciences Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 24, 2023 |
Exhibit 99.1 Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes - Neil Leatherbury Appointed Senior Vice President, Head of CMC – - Derek Jantz, Ph.D., to Assume Advisory Position of Co-Founder and Chief Science Advisor – - Jeff Smith, Ph.D., Co-Founder and Chief Research Officer Continues to Lead Research Strategy and Day-to-Day Execution of the Research Funct |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 14, 2023 |
DTIL / Precision BioSciences Inc / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-dtil123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Precision BioSciences Inc. (Name of Issuer) Common Stock, par value $0.000005 per share (Title of Class of Securities) 74019P108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| February 13, 2023 |
DTIL / Precision BioSciences Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Precision BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74019P108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 9, 2023 |
DTIL / Precision BioSciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01701-precisionbiosciences.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Precision BioSciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 74019P108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| January 27, 2023 |
DTIL / Precision BioSciences Inc / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No: 1)* Precision BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.000005 per share (Title of Class of Securities) 74019P108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 9, 2023 |
Exhibit 99.1 Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones DURHAM, N.C.—(BUSINESS WIRE)—January 9, 2023—Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 a |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2022 Precision BioSciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38841 20-4206017 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 10, 2022 |
Exhibit 99.1 Precision BioSciences Announces Change to its Board of Directors - Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company?s Scientific Advisory Board (SAB) DURHAM, N.C.- Nov. 10, 2022- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS?-based ex vivo allogeneic CAR T and in vivo gene edit |
|
| November 8, 2022 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT AMENDMENT This Executive Employment Agreement Amendment (the “Amendment”) is made as of November 7, 2022, by and among Precision BioSciences, Inc. (the “Company”) and the individual whose name appears on the signature page hereto (the “Executive”). Except as set forth in this Amendment, capitalized terms used but not defined herein shall have the meaning |
|
| November 8, 2022 |
EX-99.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation |
|
| November 8, 2022 |
Exhibit 99.1 Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update - Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 - Abstract Showcasing Functional Attributes of Azer-cel (PBCAR1091) Accepted for Presentation at the 64th American Society of Hematology (ASH) Annual Meeting - Preclinical Research on In Vivo Gene Editing Programs |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| November 8, 2022 |
Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT AMENDMENT This Executive Employment Agreement Amendment (the “Amendment”) is made as of November 7, 2022, by and among Precision BioSciences, Inc. (the “Company”) and the individual whose name appears on the signature page hereto (the “Executive”). Except as set forth in this Amendment, capitalized terms used but not defined herein shall have the meaning |
|
| November 8, 2022 |
Exhibit 10.4 EXECUTIVE EMPLOYMENT AGREEMENT AMENDMENT This Executive Employment Agreement Amendment (the “Amendment”) is made as of November 7, 2022, by and among Precision BioSciences, Inc. (the “Company”) and the individual whose name appears on the signature page hereto (the “Executive”). Except as set forth in this Amendment, capitalized terms used but not defined herein shall have the meaning |
|
| November 8, 2022 |
Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT AMENDMENT This Executive Employment Agreement Amendment (the “Amendment”) is made as of November 7, 2022, by and among Precision BioSciences, Inc. (the “Company”) and the individual whose name appears on the signature page hereto (the “Executive”). Except as set forth in this Amendment, capitalized terms used but not defined herein shall have the meaning |
|
| November 8, 2022 |
Exhibit 10.6 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of this 7h day of November, 2022 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and James Jefferson Smith (“Executive”). The Company and Executive are sometimes referred to in this Agreement individually as a “Party” and collectively as |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 1, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Comm |
|
| September 2, 2022 |
Precision BioSciences Announces Senior Leadership Organizational Changes EX-99.1 2 dtil-ex991.htm EX-99.1 Exhibit 99.1 Precision BioSciences Announces Senior Leadership Organizational Changes DURHAM, N.C.—Sep 2, 2022- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities withi |
|
| August 31, 2022 |
DTIL / Precision BioSciences Inc / JANTZ DEREK - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Precision BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74019P10 |
|
| August 26, 2022 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Precision BioSciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2019 Incentive Award |
|
| August 26, 2022 |
Amendment to the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan. Exhibit 99.4 AMENDMENT TO THE PRECISION BIOSCIENCES, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS AMENDMENT TO THE PRECISION BIOSCIENCES, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this ?Amendment?), is effective as of August 22, 2022, the date the board of directors (the ?Board?) of Precision BioSciences, Inc., a Delaware corporation (the ?Company?), approved the amendment |
|
| August 26, 2022 |
As filed with the Securities and Exchange Commission on August 26, 2022 As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| August 8, 2022 |
EX-10.5 3 dtil-ex105250.htm EX-10.5 Exhibit 10.5 SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Seventh Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of May 27, 2022, by and among PACIFIC WESTERN BANK, a California state-chartered bank (“Bank”), PRECISION BIOSCIENCES, INC. (“Precision”), and PRECISION PLANTSCIENCES, INC. f/k/a ELO LIFE SYSTEMS, INC. (“PlantS |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commiss |
|
| August 8, 2022 |
Exhibit 99.1 Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update - Launched Exclusive In Vivo Gene Insertion Collaboration with Novartis to Develop Single ARCUS Nuclease as Potential One-time Hemoglobinopathy Treatment - Extended Cash Runway to End of 2024 - Reported Updates Across Allogeneic CAR T Pipeline; Interim Results from Lead PBCAR0191 Study wit |
|
| August 8, 2022 |
Non‑Employee Director Compensation Plan (as amended). Exhibit 10.4 Precision BioSciences, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the ?Board?) of Precision BioSciences, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program, as amended from time to time (this ?Program?). The cash and equity compensation described in this Pr |
|
| July 18, 2022 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissi |
|
| July 1, 2022 |
DTIL / Precision BioSciences Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 27, 2022 |
DTIL / Precision BioSciences Inc / NOVARTIS PHARMA AG - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 27, 2022 |
EXHIBIT 2 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0. |
|
| June 27, 2022 |
Evidence of Signatory Authority EXHIBIT 1 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis Pharma AG Identification number Legal status Entry Cancelled Carried CH-270. |
|
| June 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissi |
|
| June 22, 2022 |
Underwriting Agreement, dated June 21, 2022, between the Company and Jefferies LLC. EX-1.1 2 dtil-ex11116.htm EX-1.1 Exhibit 1.1 Precision BioSciences, Inc. 35,971,224 Shares of Common Stock, par value $0.000005 per share Underwriting Agreement June 21, 2022 Jefferies LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Precision BioSciences, Inc., a Delaware corporation (the “C |
|
| June 22, 2022 |
Precision BioSciences Announces $50 Million Offering of Common Stock Exhibit 99.1 Precision BioSciences Announces $50 Million Offering of Common Stock DURHAM, N.C.?June 21, 2022 ? Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of a |
|
| June 22, 2022 |
35,971,224 Shares Common Stock Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-238857 PROSPECTUS SUPPLEMENT (To Prospectus dated June 11, 2020) 35,971,224 Shares Common Stock We are offering 35,971,224 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?DTIL.? On June 21, 2022, the last reported sale price of our common stock on the Nasdaq Global Select Mar |
|
| June 21, 2022 |
Exhibit 10.2 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this ?Agreement?) is entered into as of June 14, 2022 (the ?Execution Date?), by and between Precision BioSciences, Inc., a corporation organized and existi |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissi |
|
| June 21, 2022 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 15, 2022, between Precision BioSciences, Inc., a Delaware corporation (the ?Company?), and Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland, with its principal business office located at Lichtstrasse 35, CH-4056 Basel, Switzerlan |
|
| June 21, 2022 |
Exhibit 99.1 Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease - Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products - Precision to Develop a Sin |
|
| June 21, 2022 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. COLLABORATION AND LICENSE AGREEMENT between NOVARTIS PHARMA AG and PRECISION BIOSCIENCES, INC. COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (?Agreement?) is entered into as of June |
|
| June 8, 2022 |
a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commiss |
|
| June 8, 2022 |
Exhibit 99.1 Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed Subjects PBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from A |
|
| May 31, 2022 |
Exhibit 99.1 Precision BioSciences Appoints Melinda Brown to Board of Directors New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 DURHAM, N.C., May 31, 2022 - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS?-based ex vivo allogeneic CAR T and in vivo gene editing therapie |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| May 12, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| May 9, 2022 |
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update - PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years - Preclinical In Vivo Gene Editing Data for Primary Hyperoxaluria Type 1 and Chronic Hepatitis |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commission |
|
| April 11, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commi |
|
| March 29, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement. ?? ? ? C |
|
| March 29, 2022 |
TABLE OF CONTENTS ? SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy |
|
| March 15, 2022 |
Exhibit 99.1 Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update - Advancing ARCUS? Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the American Society of Hematology Meeting Showing High Response Rates to PBCA |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commiss |
|
| March 15, 2022 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PRECISION BIOSCIENCES, INC. ELO LIFE SYSTEMS, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (the ?Agreement?) is entered into as of May 15, 2019, by and between PACIFIC WESTERN BANK, a California |
|
| March 15, 2022 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2021, Precision BioSciences, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). References herein to ?we,? ?us,? ?our? and the ?Company? refer to Precision Bi |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38841 Precision BioSc |
|
| March 15, 2022 |
Exhibit 10.12 LEASE BIOPOINT INNOVATION LABS DURHAM TW ALEXANDER, LLC, a Delaware limited liability company as Landlord, and PRECISION BIOSCIENCES, INC., a Delaware corporation, as Tenant. TABLE OF CONTENTS Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 4 2. LEASE TERM; OPTION TERM 6 3. BASE RENT 8 4. ADDITIONAL RENT 9 5. USE OF PREMISES 15 6. SERVICES AND UTILITIES 20 7. REPAIRS 22 8. ADDI |
|
| March 15, 2022 |
Subsidiaries of Precision BioSciences, Inc. Exhibit 21.1 SUBSIDIARIES OF PRECISION BIOSCIENCES, INC. Legal Name of Subsidiary Jurisdiction of Organization Precision PlantSciences, Inc. Delaware Precision BioSciences UK Limited England and Wales |
|
| February 11, 2022 |
DTIL / Precision BioSciences Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Precision BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74019P108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2022 |
DTIL / Precision BioSciences Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Precision BioSciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 74019P108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b |
|
| February 10, 2022 |
DTIL / Precision BioSciences Inc / JANTZ DEREK - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Precision BioSciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74019P10 |
|
| January 10, 2022 |
a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2022 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Comm |
|
| January 10, 2022 |
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference Exhibit 99.1 Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference DURHAM, N.C., January 4, 2022 - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS? genome editing platform, today announced that Michael Amoroso, Chief Executive Officer will present a |
|
| December 21, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Co |
|
| December 21, 2021 |
Precision BioSciences Completes Spin-Out of Elo Life Systems Exhibit 99.1 Precision BioSciences Completes Spin-Out of Elo Life Systems DURHAM, N.C., December 21, 2021 - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS? genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by Accelr8 t |
|
| December 13, 2021 |
a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Co |
|
| November 10, 2021 |
Consulting Agreement between Precision BioSciences, Inc. and Dr. David Thomson, dated July 2, 2021. Exhibit 10.4 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential CONSULTING AGREEMENT This CONSULTING AGREEMENT (?Agreement?) is made by and between Precision BioSciences, Inc., a Delaware corporation having a place of business at 302 East Pettigrew Street, Dibrell Building, Su |
|
| November 10, 2021 |
Exhibit 10.2 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT This First Amendment to Development and License Agreement (?First Amendment?) is entered into as of August 9, 2021 (the ?First Amendment Effective Date?) by and |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Comm |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| November 10, 2021 |
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update - Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth, Ph.D., and Shari Lisa Pir?, J.D., Appointed to Board of Directors - Hosted In Vivo Gene Editing R&D Event and Outlined Plans for Accelerated Path to Clinic for Three Investigationa |
|
| November 8, 2021 |
Exhibit 99.1 Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Pir?, J.D. to Board of Directors New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience DURHAM, N.C.-(BUSINESS WIRE)?November 8, 2021- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS? genome editing platform to develop a |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commi |
|
| October 21, 2021 |
Exhibit 99.1 Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021 DURHAM, N.C.?October 21, 2021- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS? genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Derek Jantz, Ph.D., Chief Scien |
|
| October 21, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commi |
|
| September 27, 2021 |
Exhibit 10.1 Executive EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is made and entered into as of September 18, 2021, by and between Precision BioSciences, Inc. (the ?Company?), and Michael Amoroso (?Executive?). The Company and Executive are sometimes referred to in this Agreement individually as a ?Party? and collectively as the ?Parties.? BACKGROUND The Company wi |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Com |
|
| September 27, 2021 |
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer Exhibit 99.1 Precision BioSciences Appoints Michael Amoroso Chief Executive Officer DURHAM, N.C., September 27, 2021 - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the Company?s President and Chief Execu |
|
| September 27, 2021 |
Exhibit 99.2 Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., September 27, 2021 - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS? genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an |
|
| September 9, 2021 |
Exhibit 99.2 Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies iECURE to License Precision?s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE iECURE Expects to File a Clinical Trial Application as E |
|
| September 9, 2021 |
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline Exhibit 99.1 Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline - Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022, Primary Hyperoxaluria Type 1 in 2023, and Chronic Hepatitis B in 2024 - Announced Licensing |
|
| September 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Comm |
|
| September 7, 2021 |
2021 Employment Inducement Incentive Award Plan, and form of award agreements thereunder Exhibit 99.3 PRECISION BIOSCIENCES, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. Purpose The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ART |
|
| September 7, 2021 |
As filed with the Securities and Exchange Commission on September 7, 2021 Registration No. |
|
| August 12, 2021 |
EX-10.5 2 dtil-ex10530.htm EX-10.5 Exhibit 10.5 AMENDED AND RESTATED Executive EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is made and entered into as of May 27, 2021 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Alex Kelly (“Executive”). The Company and Executive are sometimes referred to in this Agreeme |
|
| August 12, 2021 |
Exhibit 99.1 Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update - Presented Interim Data Showing PBCAR0191 with Enhanced Lymphodepletion Yielded Overall Response Rate of 75% and Complete Response Rate of 50% at Day ? 28 - Dosed First Patient in CD19-Targeted Phase 1 Clinical Trial with PBCAR19B Immune-Evading Stealth Cell - Precision to Host First In V |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38841 Precision BioSciences, Inc. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commis |
|
| July 8, 2021 |
EX-99.1 2 dtil-ex9916.htm EX-99.1 Exhibit 99.1 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential CONSULTING AGREEMENT This CONSULTING AGREEMENT (“Agreement”) is made by and between Precision BioSciences, Inc., a Delaware corporation having a place of business at 302 East Pett |
|
| July 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| July 7, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| June 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| June 4, 2021 |
Exhibit 99.1 Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma Company Reports Updated Phase 1/2a Interim Study Results for 12 R/R Non-Hodgkin Lymphoma Patients who Received PBCAR0191 CAR T Cells Following Enhanced Lymphodepletion (eLD) - Median Interval of 1 Day from Enrollment to Start of Lymphodepleti |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38841 20-4206017 (State or other jurisdiction of incorporation) (Commissio |
|
| May 27, 2021 |
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer EX-99.1 3 dtil-ex9916.htm EX-99.1 Exhibit 99.1 Precision BioSciences Appoints Alex Kelly as Chief Financial Officer DURHAM, N.C., May 27, 2021 - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief Financial |
|
| May 27, 2021 |
EX-10.1 2 dtil-ex1017.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED Executive EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is made and entered into as of May 27, 2021 (the “Effective Date”), by and between Precision BioSciences, Inc. (the “Company”), and Alex Kelly (“Executive”). The Company and Executive are sometimes referred to in this Agreemen |
|
| May 13, 2021 |
Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential PROGRAM PURCHASE AGREEMENT THIS PROGRAM PURCHASE AGREEMENT (this ?Agreement?), effective as of April 9, 2021 (the ?Effective Date?), is made and entered into by and among LES LABORATOIRES SERVIER, a corporation in |
|
| May 13, 2021 |
Non-Employee Director Compensation Plan (as amended) Exhibit 10.4 Precision BioSciences, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the ?Board?) of Precision BioSciences, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program, as amended from time to time (this ?Program?). The cash and equity compensation described in this Pr |
